4.5 Article

3-Methyladenine can depress drug efflux transporters via blocking the PI3K-AKT-mTOR pathway thus sensitizing MDR cancer to chemotherapy

期刊

JOURNAL OF DRUG TARGETING
卷 22, 期 9, 页码 839-848

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/1061186X.2014.936870

关键词

3-Methyladenine; drug efflux transporters; multi-drug resistance; PI3K-AKT-mTOR pathway

资金

  1. Taizhou University Research Fund [0104010004]
  2. Zhejiang Science and Technology Department Fund [2010R50033]
  3. Jiangxi Education Fund [GJJ10613n]

向作者/读者索取更多资源

Multi-drug resistance (MDR) cancer is an intractable problem. Over-expression of drug efflux transporters such as ABCB1, ABCC1 and ABCG2 contributes to it, by which they pump drugs out of cells, and result in the decrease in the efficacy of chemotherapy. To reverse the cancer MDR, we used 3-methyladenine (3-MA) treatment on taxol or doxorubicin stressed MDR cell lines A2780DX5 and SGC7091R and xeno-tumor implanted mice. The results indicate that ABCB1, ABCC1 and ABCG2 were depressed, and the PI3K-AKT-mTOR pathway was blocked. Moreover, using FITC-labeled taxol as the indicator, we observed that the drug accumulation was enhanced in MDR cells and more cells were killed after 3-MA administration. Thus suggesting that 3-MA can reverse cancer MDR via depressing agent-efflux transporters.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据